Previous 10 | Next 10 |
Ultragenyx is a leader in rare diseases, with 4 approved products and 6 pipeline programs. They have $1bn in cash. This $5bn company is an emerging midsize pharma with no negative aspects anywhere. For further details see: Ultragenyx Is A Rare Disease Alpha Player
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
Credit Suisse has upgraded UltraGenyx (NASDAQ:RARE) to outperform from neutral citing the company's potential risk/reward ahead of a program update on its Angelman Syndrome candidate. The firm also raised its target price to $105 from $99 (~65% return based on Tuesday's close). Analyst Martin...
NOVATO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D...
The following slide deck was published by Ultragenyx Pharmaceutical Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Ultragenyx Pharmaceutical Inc. 2021 Q4 - Results - Earnings Call Presentation
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2021 Earnings Conference Call February 10, 2022 .05:00 PM ET Company Participants Joshua Higa - Senior Director of Investor Relations Emil Kakkis - President, Chief Executive Officer & Director Erik Harris - Executive Vice President & Chief Com...
Ultragenyx Pharmaceutical press release (NASDAQ:RARE): Q4 GAAP EPS of -$1.79 misses by $0.44. Revenue of $83.4M (-8.9% Y/Y) misses by $0.28M. The company expects 2022 revenue for Crysvita in Ultragenyx territories to be between $250M and $260M and Dojolvi revenue to be between $55M and $65M. ...
2021 total revenue of $351.4 million and 2021 Crysvita® revenue in Ultragenyx territories 1 of $192.6 million 2022 Crysvita revenue in Ultragenyx territories guidance of $250 million to $260 million and Dojolvi revenue of $55 million to $65 million Stron...
NOVATO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference ca...
Ultragenyx Pharmaceutical (NASDAQ:RARE) granted two newly hired non-executive officers non-qualified stock options to buy a total of 16.05K common shares and 5,350 restricted stock units under the company's Employment Inducement Plan. The stock options have a ten-year term and an ex...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...